Breaking Down Noevir Holdings Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Noevir Holdings is a steady dividend play or a growth sleeper? This chapter peels back the numbers: fiscal 2025 revenue of ¥64.72 billion (TTM) with quarterly revenue of ¥17.44 billion and five‑year revenue CAGR of ~5.9%, a net income of ¥8.03 billion for the year, a robust trailing‑12‑month ROE of 16.73%, and a declared dividend of ¥230.00 per share (5.03% yield); we also dissect margins (operating margin 17.8% H1), valuation (P/S 2.42, P/E ~19.6, P/B 2.90), liquidity shifts (¥23.59 billion cash, ¥5.81 billion operating cash inflow vs. ¥11.87 billion invested), capital structure (equity ratio ~66-68% and enterprise value ¥131.71 billion), and the key risks and growth levers that could move that ¥156.09 billion market cap-read on to follow every metric, ratio and cash‑flow driver that investors need to weigh.

Noevir Holdings Co., Ltd. (4928.T) Revenue Analysis

• Annual revenue (FY ending Sep 30, 2025): ¥64.72 billion (+1.41% YoY)
• Quarterly revenue (Q ending Sep 30, 2025): ¥17.44 billion (+11.91% YoY)
• TTM revenue: ¥64.72 billion
• Revenue per employee: ~¥47.28 million
• Price-to-Sales (P/S): 2.42
• Market capitalization: ¥156.09 billion
• Price-to-Earnings (P/E): 19.44

• Revenue per employee calculation: Total revenue ¥64.72B ÷ (approx.) number of employees ≈ ¥47.28M per employee (company-reported figure)
• Valuation multiples: Market cap ¥156.09B ÷ TTM revenue ¥64.72B = P/S 2.42; reported P/E = 19.44
• Quarterly strength: Q revenue ¥17.44B (+11.91% YoY) indicates recent acceleration within the fiscal year despite modest full-year growth

Noevir Holdings Co., Ltd. (4928.T) - Profitability Metrics

• Net income FY ending Sep 30, 2025: ¥8.03 billion (up 0.75% vs. ¥7.97 billion prior year)
• Operating income margin (1H FY2025): 17.8% (vs. 19.5% in 1H prior year)
• Net income margin (1H FY2025): 8.2% (unchanged vs. 1H prior year)
• Trailing twelve‑month ROE: 16.73%
• Trailing twelve‑month ROA: 9.28%
• Overall profit margin: 12.48%

• Margin dynamics: The slight contraction in operating margin (1H) suggests cost or mix pressures early in the year, while stable net margin implies tax/other non‑operating factors have been managed to preserve bottom‑line conversion.
• Capital efficiency: ROE of 16.73% and ROA of 9.28% reflect profitable reinvestment and asset utilization relative to peers.
• Investor focus areas: monitor operating margin recovery, revenue mix, and any changes to leverage that could affect ROE/ROA going forward.

Noevir Holdings Co., Ltd. (4928.T) - Debt vs. Equity Structure

• Equity ratio (H1 FY2025): 66.5% - indicating a majority of assets funded by shareholders' equity.
• Market capitalization: ¥156.09 billion.
• Enterprise value (EV): ¥131.71 billion - EV below market cap suggests modest net debt or net cash position.
• Price-to-book (P/B) ratio: 2.90 - market values the company at nearly 3x its book equity.
• Dividend for FY ending Sep 30, 2025: ¥230.00 per share (yield: 5.03%).
• Beta: 0.15 - substantially lower volatility than the market, consistent with conservative financing.

• Debt-to-equity: not explicitly disclosed; inferred low reliance on debt given 66.5% equity ratio and EV < market cap.
• Implication for investors: high equity ratio with low beta typically signals lower financial risk and earnings volatility.

Noevir Holdings Co., Ltd. (4928.T) - Liquidity and Solvency

• Primary drivers of cash decline: ¥11.87b invested in securities and ¥7.75b paid in dividends, exceeding operating cash inflow of ¥5.81b for the period.
• Equity ratio of 67.9% provides solvency cushion, limiting leverage risk and supporting creditworthiness.
• Short-term liquidity pressure is indicated by the ¥5.41b reduction in cash balances despite robust operating cash generation.

Noevir Holdings Co., Ltd. (4928.T) - Valuation Analysis

Noevir Holdings' current market multiples point to a company valued modestly above book and revenue benchmarks while showing reasonable enterprise-level metrics versus operating cash generation. Below are the key valuation metrics and brief implications for investors.

• Relative profitability: A TTM P/E of 19.61 vs. forward P/E 19.15 signals limited expected EPS acceleration; valuation largely reflects current earnings power rather than aggressive growth assumptions.
• Balance-sheet view: P/B of 2.90 implies investors assign a premium to intangible assets, brand value and expected return on equity beyond net tangible book.
• Revenue-based view: P/S 2.42 and EV/Revenue 1.95 together suggest the market prices both equity and enterprise value at a moderate premium to revenue - typical where margins are steady but growth is not rapid.
• Cash‑flow/operating earnings: EV/EBITDA 10.51 is within a range often considered fair-to-attractive for mature consumer goods firms; indicates reasonable price for operating cash generation.

Key considerations for investors when interpreting these multiples:

• Compare to sector peers and historical averages to judge whether the current ~19-20x P/E is rich or fair for the firm's growth and margin profile.
• Assess whether P/B ~2.9 reflects sustainable brand-driven returns on equity or temporary market optimism.
• Monitor forward earnings revisions - a downward revision would widen the effective valuation, while upgrades would justify current multiples.

For company background and broader context that complements this valuation breakdown, see: Noevir Holdings Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Noevir Holdings Co., Ltd. (4928.T) - Risk Factors

• Fluctuations in raw material costs - Noevir's cosmetics and pharmaceutical product lines depend on botanical extracts, active pharmaceutical ingredients and specialty packaging. Sharp increases in key input prices (oils, solvents, active ingredients, glass) compress gross margins, particularly where finished-product pricing is constrained by competition or channel agreements.
• Changes in consumer preferences and market trends - Shifts toward clean beauty, K‑beauty, personalization or budget brands can reduce demand for legacy premium SKUs. Slower-than-expected product adoption or poor new‑product launches can depress topline growth and increase markdowns.
• Regulatory changes in operating countries - Stricter safety/labeling requirements, new registration processes or pharmacovigilance obligations in Japan, China, ASEAN or EU markets can raise compliance costs and delay product launches, affecting time-to-revenue and operating expenses.
• Economic downturns and geopolitical tensions - Recessions, tourism declines, trade frictions or sanctions in key markets can reduce discretionary spending on cosmetics and elective pharmaceuticals, pushing revenues down and increasing channel destocking risk.
• Currency exchange rate volatility - Material portion of Noevir's revenue and costs is transacted in JPY, CNY and other Asian currencies; JPY appreciation/depreciation and CNY moves can swing reported consolidated revenue and translate into translation and transaction losses or gains.
• Competitive pressures - Domestic incumbents and multinational brands intensify pricing, promotion and R&D spend. Increased marketing and discounting to defend share can erode margins and require higher working-capital for inventory and trade promotion.

• Monitor input-cost inflation metrics (oils, active ingredients, packaging) and Noevir's gross-margin trend in quarterly reports to detect margin squeeze early.
• Watch product-segment sales mix and new product contribution: higher share of newer successful SKUs reduces vulnerability to legacy‑SKU demand shifts.
• Track regulatory filings and geographic revenue split (exposure to China, ASEAN, domestic Japan) to assess where compliance or geopolitical risk is concentrated.
• Check FX hedging disclosures and realized FX gains/losses in the income statement to understand currency risk management.
• Compare R&D and SG&A intensity versus peers to see if Noevir is maintaining competitiveness or over‑investing into promotion that may not be sustainable.

Noevir Holdings Co., Ltd. (4928.T) - Growth Opportunities

• Expansion into emerging markets: Entering Southeast Asia, India and other high-growth cosmetics markets can boost top-line growth. Target cities and market-entry scenarios should be sized against current revenue by region (replace with your revenue-by-region table below).
• New product lines and enhancements: Launch differentiated SKUs (e.g., anti-pollution, probiotic skincare, functional cosmetics). Model potential incremental revenue using SKU penetration assumptions (e.g., X% adoption among existing customers - please provide current active customer counts or average order value).
• Strategic partnerships and acquisitions: Consider acquiring niche brands or forming JV deals to access specialized ingredients, IP, or distribution networks. Assess deal size relative to Noevir's cash and leverage capacity (insert current cash, debt, and net-debt-to-EBITDA when available).
• Investing in e-commerce and digital marketing: Scale online channel by improving conversion rates, increasing average order value and lowering acquisition cost. KPI focus: website conversion, repeat purchase rate, CAC, LTV. Provide current e-commerce % of sales to model uplift scenarios.
• Sustainability and eco-friendly products: Develop biodegradable packaging and greener formulations to capture premium pricing and loyalty from environmentally conscious consumers. Estimate margin improvement or premium pricing opportunity (use current gross margin as baseline).
• Leveraging data analytics: Use purchase-history segmentation, A/B testing and recommendation engines to increase retention and basket size. Key metrics: retention rate, churn, and repeat purchase frequency - please share current metrics if available.

• Data-driven scenario examples to prepare (please provide company figures):
• Base case: maintain current channels and growth rates - requires last fiscal year revenue and growth %.
• Digital-first case: increase e-commerce penetration by Y ppt and conversion by Z% - model needs current online % of sales, conversion and AOV.
• Acquisition case: acquire a niche brand at multiple M and realize synergies - model needs cash/debt and EBITDA margins.